Hit identification

Fragment-based drug discovery (FBDD) is one strategy used to identify novel and potent lead compounds.   Don’t miss out on this free webinar, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec. The event will take place on Thursday, October 13 at 3PM BST, 4PM CET, 10AM EST, 7AM PDT. Fragments are small molecules […]

Fragment-based drug discovery (FBDD) is one strategy of hit identification (hit ID) in the drug discovery process. Register now to attend the free webinar, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec. The event will take place on Thursday, October 13 at 3PM BST, 4PM CET, 10AM EST, 7AM PDT. Key […]

Register now to attend the free webinar, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec. The event will take place on Thursday, October 13 at 3PM BST, 4PM CET, 10AM EST, 7AM PDT. Fragment-based drug discovery (FBDD) is a method used for finding hit compounds as one strategy of hit […]

Fragment-based drug discovery (FBDD) is a method used for finding hit compounds as one strategy of hit identification (hit ID) in the drug discovery process.   This free event, Introduction into Fragment Based Drug Discovery, will be hosted by DDW and supported by WuXi AppTec.  The event will take place on Thursday, October 13 at 3PM […]

Fragment-based drug discovery (FBDD) is a method used for finding hit compounds as one strategy of hit identification (hit ID) in the drug discovery process.   This free event, Introduction into Fragment Based Drug Discovery, will be hosted by DDW and supported by WuXi AppTec.  The event will take place on Thursday, October 13 at 3PM BST, […]

The latest free-to-listen DDW podcast episode is titled “Using biotechnology to maximise drug discovery output”. It covers two articles written for Volume 22, Issue 2 – Spring 2021 of the Drug Discovery World Magazine and has been narrated by DDW’s Megan Thomas.  These articles are titled: “The important integration of medicinal chemistry in Hit-to-Lead discovery” and “With so many technologies for genetically […]

APEIRON Biologics, a biotech company developing breakthrough therapies to treat cancer and respiratory conditions, has selected Domainex to provide integrated lead optimisation services in order to advance the development of inhibitors for the E3 ubiquitin ligase Cbl-b through small molecule drug discovery. Under the terms of the agreement, Domainex, an integrated drug discovery research service […]